Voltage-gated sodium channel protein type 1 subunit alpha (SCN1A) (SCN1A)

Voltage-gated sodium channel protein type 1 subunit alpha (Nav1.1) is a critical transmembrane protein primarily expressed in the central nervous system, where it plays a vital role in the initiation and propagation of action potentials, especially within inhibitory GABAergic interneurons (UniProt P35498). It consists of a large pore-forming alpha subunit that transitions between closed, open, and inactivated states in response to changes in membrane potential (PubMed: 25659481). Mutations in the SCN1A gene are a leading cause of genetic epilepsies, including Dravet syndrome, where loss of function leads to reduced interneuron activity and subsequent network hyperexcitability (NIH GeneReviews: NBK1318). Local anesthetics such as ropivacaine target Nav1.1 along with other sodium channel isoforms to provide regional anesthesia by inhibiting sodium conductance in sensory nerves (StatPearls: Ropivacaine). However, because Nav1.1 is also present in the heart and brain, non-selective blockade or genetic dysfunction can lead to significant neurological and cardiovascular complications (PubChem CID 175030). Understanding the specific role of Nav1.1 is crucial for developing targeted therapies for seizure disorders and managing the side effects of non-selective sodium channel blockers (PubMed: 30541864).

Other names

Nav1.1Voltage-gated sodium channel subunit alpha type ISCN1NAC1FEB3GEFSP2HBSCI (UniProt P35498)

Ropivacaine and other local anesthetics bind to the S6 segment of domain IV in the alpha subunit of the voltage-gated sodium channel, physically blocking the pore and stabilizing the inactivated state of the channel to prevent sodium influx and nerve impulse conduction (StatPearls: Ropivacaine; PubMed: 10657236).